Will this news trigger a short‑term price movement in ANIX shares?

Short‑term outlook:

The new U.S. patent that extends the life of Anixa’s solid‑tumor CAR‑T platform until 2045 is a clear, material catalyst for the stock. In biotech, patent extensions are one of the few events that can materially de‑risk a company’s pipeline and therefore tend to generate immediate buying pressure. The press‑release carries a strong positive sentiment score (70) and is likely to be amplified by sector‑wide news‑feeds and analyst coverage, which historically translates into a 10‑15 % upside in the next 1‑3 days for similar small‑cap CAR‑T firms.

Technical context:

ANIX has been trading in a tight range around the $1.20–$1.35 band for the past two weeks, with the 20‑day SMA hovering near $1.28 and the daily volume averaging 150 k shares—well below the 300 k‑share “high‑vol” threshold that typically fuels a breakout. The patent news should push volume above that level, breaking the upper resistance near $1.33. If the price can clear $1.35 on strong volume, the next swing‑high target is the 50‑day EMA at $1.45; a failure to hold $1.33 would likely snap the short‑term rally and re‑establish the $1.20 support.

Actionable take‑away:

Given the fundamental upside and the technical setup, a short‑term long position (or a “buy‑the‑dip” if the stock pulls back to $1.28) is justified for traders looking to capture the immediate catalyst‑driven bounce. Tight stop‑losses just below the $1.30‑$1.31 level (or the $1.28 SMA) will protect against a quick reversal if the broader market turns bearish or the news is already priced in. If the rally stalls at $1.35, consider scaling out and letting the stop‑loss trail to lock in gains while the longer‑term upside to $1.45 remains intact.